Terres W, Becker B F, Schrödl W, Gerlach E
Department of Physiology, University of Munich, West Germany.
Cardiovasc Res. 1989 Feb;23(2):112-6. doi: 10.1093/cvr/23.2.112.
Most of our knowledge about the modulation of platelet function by catecholamines is based on observations of acute in vitro actions. Little is known about the effects of chronically elevated or reduced adrenergic stimulation of the platelets. We therefore treated rats for 8 weeks with either adrenaline or the beta-blocker propranolol. Adrenaline (0.5 mg.kg-1.d-1) continuously administered from subcutaneously implanted osmotic mini pumps caused an increase in the sensitivity of the platelets towards ADP as stimulating agent. In contrast, chronic application of propranolol (10 mg.kg-1.d-1) via the drinking water led to a reduction in platelet aggregability. For animals treated with adrenaline, in accordance with the results of the aggregation experiments, the levels of c-AMP found in platelet rich plasma were reduced, both basally (by 33%) and after stimulation of platelet adenylate cyclase with prostaglandin E1 (by 39%). For the propranolol treated animals, the basal c-AMP concentrations remained unchanged. The levels of c-AMP attained after stimulation with prostaglandin E1 were diminished to a similar extent as for the adrenaline treated animals (by 38%). Although the in vitro addition of adrenaline to platelet rich plasma causes a beta-adrenoceptor mediated inhibition of platelet aggregation in the rat, the simulation seen after chronic adrenaline exposure in vivo, which is associated with decreases in both basal and stimulated c-AMP levels, suggests a functional preponderance of alpha-adrenoceptors over beta-adrenoceptors on the rat platelets. Although intraplatelet metabolic changes (blockade of stimulated c-AMP formation) after chronic application of propranolol should have resulted in enhancement of platelet aggregability, an inhibition of aggregation was observed.(ABSTRACT TRUNCATED AT 250 WORDS)
我们关于儿茶酚胺对血小板功能调节的大部分知识基于对急性体外作用的观察。对于血小板长期受肾上腺素能刺激增强或减弱的影响了解甚少。因此,我们用肾上腺素或β受体阻滞剂普萘洛尔对大鼠进行了8周的治疗。从皮下植入的渗透微型泵持续给予肾上腺素(0.5毫克·千克⁻¹·天⁻¹)导致血小板对作为刺激剂的ADP的敏感性增加。相反,通过饮用水长期给予普萘洛尔(10毫克·千克⁻¹·天⁻¹)导致血小板聚集性降低。对于用肾上腺素治疗的动物,根据聚集实验结果,富含血小板血浆中发现的c - AMP水平在基础状态下降低(降低33%),在用前列腺素E1刺激血小板腺苷酸环化酶后也降低(降低39%)。对于用普萘洛尔治疗的动物,基础c - AMP浓度保持不变。用前列腺素E1刺激后达到的c - AMP水平降低程度与用肾上腺素治疗的动物相似(降低38%)。虽然在富含血小板血浆中体外添加肾上腺素会导致大鼠血小板聚集受β肾上腺素能受体介导的抑制,但体内长期暴露于肾上腺素后出现的模拟情况,与基础和刺激后的c - AMP水平降低相关,表明大鼠血小板上α肾上腺素能受体比β肾上腺素能受体功能占优势。虽然长期应用普萘洛尔后血小板内代谢变化(刺激的c - AMP形成受阻)本应导致血小板聚集性增强,但却观察到聚集受到抑制。(摘要截断于250字)